Minakem Header W48

Minakem Header W48

X

[{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Exeltis Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin Signs Distribution Agreement in Key EU Territories for Orphan Drug NaMuscla\u00ae","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Lupin Ltd"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Receives Approval for Penicillamine Tablets USP","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Lupin Ltd"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Penicillamine Tablets USP","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Lupin Ltd"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Receives USFDA Approval for Icatibant Injection, 30 mg\/3 mL (10 mg\/mL) Single-Dose Prefilled Syringe","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of A Generic Version of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg in the U.S. Market","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Dr. Reddy\\'s Laboratories"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of A Generic Version of Sapropterin Dihydrochloride Tablets for Oral Use in the U.S. Market","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Dr. Reddy\\'s Laboratories"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Penicillamine Capsules USP, 250 mg in the U.S. Market","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Dr. Reddy\\'s Laboratories"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Dr. Reddy's Laboratories

Contact Supplier

Offering a portfolio of products & services including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Contact Supplier

$Dr. Reddy\'s Laboratories$

Digital Content

Dr. Reddy's Laboratories Announces the Launch of A Generic Version of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg in the U.S. Market

Details:

The launch of Sapropterin Dihydrochloride Powder for Oral Solution, 100mg, a therapeutic equivalent generic version of Kuvan® (sapropterin dihydrochloride) Powder for Oral Solution, 100 mg, USP, is approved by the U.S. Food and Drug Administration (USFDA).

Lead Product(s): Sapropterin HCl

Therapeutic Area: Genetic Disease Product Name: Sapropterin Dihydrochloride-Generic

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 07, 2021

Dr Reddy Company Banner

CPhI India 2022

Attending

envelop Contact Supplier

Dr. Reddy's Laboratories

Contact Supplier

Offering a portfolio of products & services including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Contact Supplier

$Dr. Reddy\'s Laboratories$

Digital Content

Dr. Reddy's Laboratories Announces the Launch of A Generic Version of Sapropterin Dihydrochloride Tablets for Oral Use in the U.S. Market

Details:

The launch of generic version of Sapropterin Dihydrochloride Tablets, for Oral Use, illustrating the commitment to bring affordable generic medicines to market for patients. Dr. Reddy’s Sapropterin Dihydrochloride Tablets, 100 mg are available in bottle count sizes of 120.

Lead Product(s): Sapropterin HCl

Therapeutic Area: Genetic Disease Product Name: Sapropterin Dihydrochloride-Generic

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 03, 2020

Dr Reddy Company Banner

CPhI India 2022

Attending

envelop Contact Supplier

Dr. Reddy's Laboratories

Contact Supplier

Offering a portfolio of products & services including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Contact Supplier

$Dr. Reddy\'s Laboratories$

Digital Content

Dr. Reddy's Laboratories Announces the Launch of Penicillamine Capsules USP, 250 mg in the U.S. Market

Details:

Penicillamine-Generic is a chelating agent used in the treatment of Wilson’s disease. It is also used to reduce cystine excretion in cystinuria and to treat patients with severe, active rheumatoid arthritis unresponsive to conventional therapy.

Lead Product(s): Penicillamine

Therapeutic Area: Genetic Disease Product Name: Penicillamine-Generic

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 27, 2020

Dr Reddy Company Banner

CPhI India 2022

Attending

envelop Contact Supplier

Glenmark Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Glenmark Receives USFDA Approval for Icatibant Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe

Details:

This marks Glenmark's first synthetic decapeptide Icatibant Injection approval and will be manufactured in their North American manufacturing facility based in Monroe, North Carolina.

Lead Product(s): Icatibant Acetate

Therapeutic Area: Genetic Disease Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 24, 2021

ASK
US

Upload
your Pipeline Activity

Lupin Ltd

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Lupin Launches Penicillamine Tablets USP

Details:

Penicillamine tablets USP, 250 mg, are the generic equivalent of Depen tablets, 250 mg, of Mylan and indicated in the treatment of Wilson’s disease, Cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to conventional therapy.

Lead Product(s): Penicillamine

Therapeutic Area: Genetic Disease Product Name: Depen

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 03, 2021

ASK
US

Upload
your Pipeline Activity

Lupin Ltd

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Lupin Receives Approval for Penicillamine Tablets USP

Details:

Lupin has received approval for its Penicillamine Tablets USP, 250 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Depen® Tablets, 250 mg, of Mylan Specialty, L.P.

Lead Product(s): Penicillamine

Therapeutic Area: Genetic Disease Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 01, 2020

ASK
US

Upload
your Pipeline Activity

Lupin Ltd

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Lupin Signs Distribution Agreement in Key EU Territories for Orphan Drug NaMuscla®

Details:

Under the agreements, Exeltis Healthcare will commercialize NaMuscla® in Spain and Portugal, Cresco Pharma B.V will commercialize NaMuscla® in the Netherlands and Macure Pharma ApS in the Nordic countries. Lupin will continue commercialization of NaMuscla® in Germany and UK.

Lead Product(s): Mexiletine

Therapeutic Area: Genetic Disease Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Exeltis Healthcare

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 03, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY